642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological II


Cristina Bagacean, Rémi Letestu, Chadi Al Nawakil, et al.

See abstract for more info.



Gilad Itchaki, Lior Rokach, Ohad Benjamini, et al.

See abstract for more info.



Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, et al.

The ibrutinib regimen is able to extend the PFS compared to the BR in older patients with treatment-naive CLL. The authors of the study support ibrutinib initial therapy for CLL with their data and support the justification for ibrutinib in high-risk diseases. See abstract for more info.



Matthew S. Davids, Danielle M. Brander, Svitlana Tyekucheva, et al.

During a median follow-up of 40.3 months, most patients treated with iFCR continued to have a deep response. This also affected patients with non-mutated IGHV. The safety profile is consistent with the individual toxicities of ibrutinib and FCR. The few relapses have all responded to re-treatment with ibrutinib.


Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, et al.

The preliminary results show a lower BM-MRD rate in the IV arm after nine months compared to the FCR arm. There is still significant and relatively similar toxicity between the two arms. According to the study authors, the BM-MRD rate should improve after prolonged exposure to the IV combination. The decision to determine the best therapeutic strategy will only be possible after analyzing the primary endpoint after 27 months.




Peter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.

Ibrutinib plus rituximab resulted in a superior PFS compared to FCR with no difference in OS.